CHMP recommends EU approval of Jentadueto (Boehringer) for Type 2 Diabetes

The EMA's CHMP recommend approval of Jentadueto (linagliptin plus metformin), from Boehringer, alongside diet and exercise to improve glycaemic control in adults with Type 2 Diabetes. If approved by the EU the drug will provide a new, single-tablet treatment option for adults with Type 2 Diabetes who need to improve control of their blood glucose. The recommendation for approval was based on clinical trials that evaluated linagliptin and metformin as separate tablets. Bioequivalence of linagliptin/metformin HCl was demonstrated with co-administered linagliptin and metformin tablets in healthy subjects with Type 2 Diabetes.